HPL Pharmaceuticals: Major
Health Technology
Mkt Cap
38.6B
P/E (TTM)
12.61
EPS
300.69
ROE
37.58%
Div Yield
6.01%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 30.96B | 26.75B | 21.37B | 18.56B | 15.88B | |
| Cost of Goods Sold | -19.64B | -18.62B | -16.00B | -13.83B | -11.95B | |
| Gross Profit | 11.31B | 8.13B | 5.37B | 4.73B | 3.93B | |
| SG&A Expenses | -5.61B | -4.67B | -3.53B | -3.54B | -2.51B | |
| Depreciation | — | -295.61M | -302.94M | -282.35M | -333.04M | |
| Other Operating Expense | -336.0K | -407.07M | -107.29M | -13.24M | -26.57M | |
| Total Operating Expense | -25.26B | -23.69B | -19.64B | -17.38B | -14.48B | |
| Operating Income (EBIT) | 5.70B | 3.05B | 1.73B | 1.18B | 1.40B | |
| Interest Income | — | 4.08M | 80.88M | 1.38M | 759.0K | |
| Interest Expense | -99.86M | -144.52M | -174.77M | -49.83M | -28.43M | |
| Equity in Earnings | — | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | -645.87M | 211.51M | -979.26M | -506.93M | -58.26M | |
| Total Non-Operating Income | -745.72M | 98.98M | -1.00B | -453.51M | 38.22M | |
| Pre-Tax Income | 4.95B | 3.15B | 731.05M | 724.07M | 1.44B | |
| Income Tax | -2.05B | -1.29B | -370.24M | -557.28M | -530.50M | |
| Minority Interest | — | 0 | 0 | 0 | 0 | |
| Net Income | 2.90B | 1.86B | 360.81M | 166.78M | 905.95M | |
| EBITDA | 6.05B | 3.36B | 2.05B | 1.46B | 1.73B | |
| EPS (Basic) | 300.69 | 192.56 | 37.41 | 17.29 | 93.93 | |
| EPS (Diluted) | 300.69 | 192.56 | 37.41 | 17.29 | 93.93 | |
| Gross Margin | 36.55% | 30.38% | 25.11% | 25.49% | 24.77% | |
| Operating Margin | 18.41% | 11.41% | 8.11% | 6.34% | 8.80% | |
| EBITDA Margin | 19.56% | 12.56% | 9.58% | 7.88% | 10.92% | |
| Pre-Tax Margin | 16.00% | 11.78% | 3.42% | 3.90% | 9.05% | |
| Net Margin | 9.37% | 6.94% | 1.69% | 0.90% | 5.70% |